MDAI (21) SRTS (46) SNWV (53) TELA (36) ⌘ Pro Terminal →

Daxor Corporation (DXR) — RQD Stock Rating Cockpit

$8.92 -0.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.89

Daxor Corporation (DXR) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $52.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.89 (-0.29%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DXR)Realized 20D OHLCV Swing Band: ±8.6%

Deterministic 5-Pillar Attribution (52/100 Composite)

🔍 WHY DXR SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($1.5M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$10.41-3.5% Next Q

Q2 (-2Q)

Grade C$10.05-8% Next Q

Q3 (-1Q)

Grade C$9.25-3.6% Next Q

Current

Grade D+$8.92-1.1% Hist 90D α

Trajectory: C (60) → D+ (52)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DXR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DXR currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.43) and Max Pain ($9.37) forces dealer call-delta covering toward $15.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DXR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DXR Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 52%NO 48%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

35.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE8% OF RANGE

L: $8$8.92H: $15

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on DXR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (45)

17/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like DXR

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DXR)

✓Walkthrough of DXR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DXR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -17.41%▼ SUPPORT BREAKDOWN

2026-10-30O $8.86H $9.20L $8.40C $8.92VOL 28.0K

RES: $12.46SUP: $9.50SMA50: $10.43SMA200: $10.72

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DXR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DXR Butterfly Map → + Track DXR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DXR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DXR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DXR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DXR)

Health Care Rank #326 of 1016 ⚔️ MDAI vs DXR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DXR vs. MDAI, SRTS, SNWV, TELA)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Daxor Corporation (DXR) ranks #326 by composite RQD confidence (52/100, grade D+) and #745 by equity capitalization ($52.1M). Within this direct 5-issuer industry benchmark cohort, SNWV leads on earnings valuation at 3.8x trailing P/E, while SNWV leads on capital efficiency and profitability with 67.3% ROIC and 77.1% gross margin. SNWV currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with DXR at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DXR ACTIVE Daxor Corporation	D+	52/100	—	—	—	-0.56%	$52.1M	Benchmark Subject
MDAI Spectral AI Inc. (Class A)	E	21/100	—	45.4%	-35.0%	+0.64%	$50.5M	/mdai-vs-dxr →
SRTS Sensus Healthcare Inc.	D	46/100	—	43.2%	-31.3%	-1.77%	$45.6M	/srts-vs-dxr →
SNWV SANUWAVE Health Inc.	D+	53/100	3.8x	77.1%	67.3%	0.00%	$45.3M	/snwv-vs-dxr →
TELA TELA Bio Inc.	D-	36/100	—	67.7%	-35.0%	-5.74%	$41.5M	/tela-vs-dxr →

2. DXR Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Daxor Corporation (DXR) operates in Medical/Dental Instruments (Health Care) with an equity capitalization of $52.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. DXR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DXR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Daxor Corporation (NASDAQ: DXR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $8.92 (-0.56% 1D, market cap $52.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, DXR ranks #326 in composite RQD confidence.

How does DXR compare to MDAI and SRTS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), DXR carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MDAI (Spectral AI Inc. (Class A)) holds a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $50.5M) and SRTS (Sensus Healthcare Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -31.3%, cap $45.6M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DXR?

For Daxor Corporation (DXR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #326 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DXR trading relative to its 50-day, 200-day, and 52-week technical levels?

DXR last traded at $8.92 (-0.56% on volume of 3,668 shares), positioning the stock -14.48% below its 50-day simple moving average ($10.43) and -16.79% below its 200-day simple moving average ($10.72). Across its 52-week range of $8.40 to $14.76, DXR sits at the 8.2% percentile with a 14-day RSI of 35.4 (NEUTRAL RANGE) and an implied next-earnings move of ±8.6% ($8.15 to $9.69).

DXR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell DXR stock right now?

Daxor Corporation (DXR) currently earns a Roarable Rating of D+ (Sell — SELL) with 52/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is DXR's 12-month price target and RQD AI Jury consensus?

DXR's 12-month base price target is $8.68 (range $6.77 to $15.5), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: DXR RQD Cockpit DXR 12M Forecast DXR Earnings & Move DXR Dividends & DRIP DXR Insiders & 13F DXR Whale Options DXR Profit Sankey DXR News & Why